“Evaluation of Paclitaxel as a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC)” (2025) International Cancer Research Journal, 1(1), p. 2. doi:10.70844/icrj.2025.1.2.